Onconic Therapeutics Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	15,784	-8,093	1,682	-14,432	-15,149
Depreciation & Amortization	528.44	452.67	458.95	199.66	181.88
Other Amortization	-	-	1.18	1.18	1.08
Loss (Gain) From Sale of Assets	-	-	0.7	-	-
Stock-Based Compensation	696.53	1,026	578.03	472.48	163.17
Other Operating Activities	-2,255	4,427	-774.88	-277.64	6,829
Change in Accounts Receivable	-3,647	-7,222	104.5	-99	-5.5
Change in Accounts Payable	1,961	708.67	-	-	-
Change in Income Taxes	-	463.39	-	-	-
Change in Other Net Operating Assets	-1,673	396.57	2,094	-825.75	-879.32
Operating Cash Flow	11,395	-7,841	4,145	-14,961	-8,859
Capital Expenditures	-302.9	-141.28	-1,157	-2,575	-2.67
Sale of Property, Plant & Equipment	-	-	38	-	-
Sale (Purchase) of Intangibles	-	-	-	-	-5.88
Investment in Securities	-5,894	-	-	-	-
Other Investing Activities	-	70.42	108.76	135.75	-
Investing Cash Flow	-6,197	-70.85	-1,011	-2,439	-8.55
Long-Term Debt Repaid	-194.35	-179.92	-153.85	-142.06	-142.06
Net Debt Issued (Repaid)	-194.35	-179.92	-153.85	-142.06	-142.06
Issuance of Common Stock	1,279	19,762	-	-	7,498
Other Financing Activities	-1,611	-	-	-	-
Financing Cash Flow	-526.27	19,582	-153.85	25,858	27,356
Foreign Exchange Rate Adjustments	-625.72	1,229	-	-	-
Net Cash Flow	4,046	12,899	2,981	8,458	18,488
Free Cash Flow	11,092	-7,982	2,988	-17,536	-8,861
Free Cash Flow Margin	20.77%	-53.79%	14.19%	-18458.96%	-14769.11%
Free Cash Flow Per Share	-	-244.07	129.24	-758.49	-386.90
Cash Income Tax Paid	959.21	912.06	2,170	2.18	2.71
Levered Free Cash Flow	5,103	-50,062	16,415	13,630	-
Unlevered Free Cash Flow	5,111	-49,646	17,991	14,304	-
Change in Working Capital	-3,359	-5,653	2,199	-924.75	-884.82

Source: S&P Global Market Intelligence. Standard template. Financial Sources.